Party Drug Ketamine (Special K) Likely To Become Anti-Depression Medicine
The drug Ketamine, known in the party scene as "Special K," could have a future in depression treatment. Pharmaceutical companies are racing to create a patentable version of the drug and researchers are trying to learn more about the effects it has on the brain. Ketamine works by blocking the signalling molecule NMDA, which is a component of the glutamate pathway. This pathway is involved with memory and cognition, psychiatrist James Murrough at the Mount Sinai Hospital in New York City, explained to Nature magazine.
- Dr. James Murrough, Assistant Professor, Psychiatry, Neuroscience, Icahn School of Medicine at Mount Sinai
“Forever Chemicals” Linked to Higher Risk of Type 2 Diabetes
Jul 22, 2025 View All Press Releases
Like Humans, AI Can Jump to Conclusions, Mount Sinai Study Finds
Jul 22, 2025 View All Press Releases
Mount Sinai Researchers Engineer Rare Immune Cells to Create Powerful New Cancer Vaccine
Jul 21, 2025 View All Press Releases
Blocking a Little-Known Protein May Offer New Hope for Devastating Lung Disease
Jul 15, 2025 View All Press Releases
Prenatal and Childhood Lead Exposure Linked to Faster Memory Decay in Children
Jul 09, 2025 View All Press Releases
The New England Journal of Medicine Shines Spotlight on Forensic Pathology
Jul 03, 2025 View All Press Releases